Literature DB >> 33428793

Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta.

Takashi Hashimoto1,2, Leigh A Nattkemper1, Hei Sung Kim1, Christina D Kursewicz1, Emilie Fowler1, Serena M Shah1, Sonali Nanda1, Rachel A Fayne1, John F Paolini3, Paolo Romanelli1, Gil Yosipovitch1.   

Abstract

Prurigo nodularis (PN) is a chronic skin dermatosis with hyperkeratotic and intensely pruritic nodules. Managing PN-associated itch is difficult because its aetiology is still unknown. This study aimed to investigate the correlation between itch intensity in PN and the expression of a pruritogenic cytokine interleukin (IL)-31, its receptor complex components IL-31 receptor α (IL-31RA) and oncostatin M receptor β (OSMRβ), and oncostatin M (OSM), which is a ligand of OSMR β, through immunofluorescence staining examination. Itch intensity in PN was closely correlated with the number of dermal IL-31(+) cells (Spearman's r = 0.551, p < 0.05), dermal IL-31RA(+) cells (r = 0.475, p < 0.05) and dermal OSM(+) cells (r = 0.505, p < 0.05). In addition, the number of dermal OSMRβ (+) cells was increased in PN (t test, p < 0.05), despite not being correlated with itch intensity (Spearman's r = 0.375, p > 0.05). Major cellular sources of dermal IL-31 were T cells (27.0% of total IL-31-expressing cells) and macrophages (35.0%), while those of OSM were mainly T cells (49.8%) and mast cells (26.8%). IL-31RA-expressing dermal cells were mostly mast cells (49.3%) and macrophages (36.6%), and OSMRβ was mainly expressed by macrophages (51.8%) in the dermis. These findings indicate that IL-31 (mainly from macrophages and T cells) and OSM (principally from T cells and mast cells) stimulate dermal cells expressing IL-31RA and OSMRβ (e.g. macrophages), which may further promote itch and inflammation in PN. This complex dermal milieu of cell/cytokine/receptor network can be a therapeutic target for PN-associated itch.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  IL-31; IL-31 receptor; itch; oncostatin M; prurigo nodularis

Mesh:

Substances:

Year:  2021        PMID: 33428793     DOI: 10.1111/exd.14279

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  12 in total

Review 1.  IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses.

Authors:  Youkyung S Roh; Justin Choi; Nishadh Sutaria; Micah Belzberg; Madan M Kwatra; Shawn G Kwatra
Journal:  Drugs       Date:  2021-04-21       Impact factor: 9.546

Review 2.  [Update on the treatment of chronic prurigo].

Authors:  Claudia Zeidler; Manuel Pedro Pereira; Sonja Ständer
Journal:  Dermatologie (Heidelb)       Date:  2022-07-12

Review 3.  Pruritus in Keloid Scars: Mechanisms and Treatments.

Authors:  Ahmed A Hawash; Giuseppe Ingrasci; Keyvan Nouri; Gil Yosipovitch
Journal:  Acta Derm Venereol       Date:  2021-10-28       Impact factor: 3.875

4.  Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab.

Authors:  Lam C Tsoi; Feriel Hacini-Rachinel; Paul Fogel; Francois Rousseau; Xianying Xing; Matthew T Patrick; Allison C Billi; Celine C Berthier; J Michelle Kahlenberg; Anne Lazzari; Henning Wiegmann; Sonja Ständer; Christophe Piketty; Valerie Julia; Jayendra Kumar Krishnaswamy; Johann E Gudjonsson
Journal:  J Allergy Clin Immunol       Date:  2021-11-29       Impact factor: 14.290

Review 5.  Atopic dermatitis: an expanding therapeutic pipeline for a complex disease.

Authors:  Thomas Bieber
Journal:  Nat Rev Drug Discov       Date:  2021-08-20       Impact factor: 84.694

Review 6.  Immunotargets and Therapy for Prurigo Nodularis.

Authors:  Angelina Labib; Teresa Ju; Ashley Vander Does; Gil Yosipovitch
Journal:  Immunotargets Ther       Date:  2022-04-26

7.  High Serum IL-31 Concentration Is Associated with Itch among Renal Transplant Recipients.

Authors:  Piotr K Krajewski; Kinga Tyczyńska; Klaudia Bardowska; Piotr Olczyk; Danuta Nowicka-Suszko; Dariusz Janczak; Hanna Augustyniak-Bartosik; Magdalena Krajewska; Jacek C Szepietowski
Journal:  J Clin Med       Date:  2022-07-25       Impact factor: 4.964

Review 8.  Eosinophils in skin diseases.

Authors:  Susanne Radonjic-Hoesli; Marie-Charlotte Brüggen; Laurence Feldmeyer; Hans-Uwe Simon; Dagmar Simon
Journal:  Semin Immunopathol       Date:  2021-06-07       Impact factor: 9.623

Review 9.  Pruritus as a Distinctive Feature of Type 2 Inflammation.

Authors:  Simone Garcovich; Martina Maurelli; Paolo Gisondi; Ketty Peris; Gil Yosipovitch; Giampiero Girolomoni
Journal:  Vaccines (Basel)       Date:  2021-03-23

Review 10.  Pruritus: A Sensory Symptom Generated in Cutaneous Immuno-Neuronal Crosstalk.

Authors:  Attila Gábor Szöllősi; Attila Oláh; Erika Lisztes; Zoltán Griger; Balázs István Tóth
Journal:  Front Pharmacol       Date:  2022-03-07       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.